Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05003882 · ClinicalTrials.gov registry record
Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting
A clinical trial, sponsored by Radicle Science.
- Completed
- Registry status
- 3,000
- Enrollment target
NCT05003882: Completed study, sponsored by Radicle Science.
NCT05003882 is a clinical trial that has completed, run by Radicle Science. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05003882 has completed, sponsored by Radicle Science.
- COMPLETED
- Registry status
- 3,000 participants
- Enrollment target
Study Summary
A randomized, open-label study of commercially available, orally ingestible, Cannabidiol (CBD) products used in the real-world setting for pain, sleep, and anxiety.
Primary Outcome
Overall well-being as assessed by KEMP Quality of Life Scale (QOL scale 1-7 where 7 is a better QOL)
Interventions
- OTHER Commercially available, orally ingestible CBD product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2021-12-31 |
What the finished NCT05003882 record still lists
NCT05003882 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Commercially available, orally ingestible CBD product is the first listed.
NCT05003882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05003882 about?
NCT05003882 is a clinical study titled "Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting". A randomized, open-label study of commercially available, orally ingestible, Cannabidiol (CBD) products used in the real-world setting for pain, sleep, and anxiety.
What is the current status of trial NCT05003882?
This trial is currently completed. The enrollment target is 3,000 participants. The study started on 2021-08-02. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT05003882?
The interventions under investigation include: Commercially available, orally ingestible CBD product (OTHER).
Who is sponsoring clinical trial NCT05003882?
This trial is sponsored by Radicle Science, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI